MSM Complex tablet
MSM Complex tablet, licence 80126044: active licence in Health Canada data. The French and European references below do not constitute authorisation for sale in France or an assessment of safety or efficacy.
Licensed Natural Health Products Database (LNHPD), Health Canada: licensed products, ingredients, doses, uses and risks, retrieved 27 October 2026.
Contains information licensed under the Open Government Licence – Canada (Health Canada, LNHPD)
Licence du gouvernement ouvert – Canada 2.0 (OGL-Canada 2.0)
Natural health product licensed in Canada
- Other names
- BOOMHUE Joint complex, CTC Health Care Joint complex, MEIKAXIONG Joint complex, NURIS Joint complex, REAPS Joint complex, Vican Joint complex
- Licence holder
- JEM Bioscience Ltd.
- NPN or DIN-HM
- 80126044
- Status
- Active licence
- Licence date
- 9 August 2023
- Revision date
- Not provided
- Form
- Comprimé, enrobé par pellicule
- Route of administration
- Orale
- Application type
- Officinale
If this product were sold in France
No point flagged by the rules we apply.
A daily quantity is calculated only for an explicit adult oral dosage, stated per day and in a solid unit matching the product form. Ambiguous units, liquids, powders and paediatric doses are not extrapolated. A quantity not calculated is not compared with dose limits. This analysis does not constitute authorisation for sale in France or an assessment of safety or efficacy.
Composition
Medicinal composition not provided.
Non-medicinal ingredients
Cellulose microcristalline, Dioxyde de silicium, Dioxyde de titane, Stéarate de magnésium, Hydroxypropyl méthylcellulose, Croscarmellose de sodium, Poly(alcool vinylique)
Recommended doses in Canada
| Population | Age | Quantity per serving | Frequency |
|---|---|---|---|
| Adultes | minimum: 18.0 ans | 1.0 Comprimé | 1.0 Jour(s) |
Uses authorised in Canada
Text supplied in English because no French text is available.
Helps in the development and maintenance of bones. Helps to relieve (joint) pain associated with osteoarthritis (of the knee). Vitamin D intake, when combined with sufficient calcium, a healthy diet, and regular exercise, may reduce the risk of developing osteoporosis.
A use authorised in Canada is not an authorised health claim in the European Union. See the health claims register.
Warnings in Canada
No French warning text available in the imported data.
Warnings are available in English on the official record.
Source
Official Health Canada record, licence 80126044
The formula sold in Europe under the same name may differ. This information does not replace advice from a doctor or pharmacist.
The evidence date of this ingredient list is unknown.
Has the product changed? Photograph the packaging.